Drug Development
Roche said the Phase II results help build the case for advancing CT-388 into late-stage testing, which is set to get underway this quarter.
FEATURED STORIES
As drug candidates discovered via AI move into later-stage clinical trials, the technology seems to be doing as promised: speeding drug development.
Following the hard-won success of early anti-amyloid drugs, a new generation of Alzheimer’s modalities—from tau-targeting gene silencers to blood-brain barrier delivery platforms—is entering the pipeline to anchor future combination therapies.
Three years after the accelerated approval of its anti-amyloid Alzheimer’s therapy, Biogen—neck and neck in the market with Eli Lilly and its Kisunla offering—is focused on a near-term FDA decision for a subcutaneous induction dose of Leqembi, a presymptomatic readout in 2028 and a clutch of next-generation candidates.
Subscribe to ClinicaSpace
Clinical trial results, research news, the latest in cancer and cell and gene therapy, in your inbox every Monday
THE LATEST
Biopharma and life sciences companies from across the globe provide updates to their businesses and pipelines.
PCN-101 was recently awarded Investigational New Drug (IND) status by the U.S. Food and Drug Administration. It’s a for treating the patients with treatment resistant depression.
The job cuts were announced as part of an organizational streamlining initiative that will refocus resources toward the company’s highest-value activities.
Pardes is funneling the funds into financing the next stage of clinical trials and commercial production of its lead oral antiviral drug, PBI-0451, for the treatment and prevention of SARS-CoV-2 infections.
One hundred percent of test serum samples showed neutralization of the delta variant, and more than ninety percent of serum samples showed neutralization of the Omicron variant.
According to the Environmental Litigation Group, P.C., approximately 37.5% of all occupational lung cancer cases are related to occupational asbestos exposure.
The FDA informed Johnson & Johnson that adverse-event reports indicated a possible increased risk of immune thrombocytopenia within 42 days after vaccination with their COVID-19 vaccine.
The Centers for Medicare and Medicaid Services indicated it would cover the cost of these drugs and any necessary scans — but only “if they are enrolled in qualifying clinical trials.”
Sanofi will pay ABL $75 million upfront, and the latter is eligible to receive as much as $985 million down the line as development, regulatory, and commercialization milestones are met.
T follicular helper immune cells help antibody-producing cells create increasingly robust antibodies and also enhance the formation of certain types of immune memory.